CASI Pharmaceuticals to Be Delisted from Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Source: NASDAQ.COM
- Delisting Notification: CASI Pharmaceuticals received a determination letter from the Nasdaq Hearings Panel on February 23, 2026, indicating that its securities will be delisted on February 26, 2026, due to failure to meet continued listing requirements, highlighting significant compliance challenges for the company.
- Market Transition: Although the company does not intend to request a review, its ordinary shares will move to the OTC market, with CASI cautioning that there is no guarantee brokers will maintain a market, potentially impacting liquidity and reflecting a lack of market confidence.
- R&D Progress: CASI remains focused on advancing CID-103, a fully human IgG1 monoclonal antibody for organ transplant rejection and autoimmune diseases, having received regulatory approvals for clinical trials in China and the U.S., demonstrating the company's ongoing commitment to research and development.
- Stock Price Volatility: CASI's stock closed at $0.21 on Wednesday, down 74.06%, but rose 34.94% to $0.28 in premarket trading on Thursday, indicating mixed market expectations regarding the company's future prospects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
